All In Biotech

Free tool

FAERS Monitor: Sarclisa Escena

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761445 or its brand name (Sarclisa Escena, Isatuximab-Irfc). Reports on generic versions are filed under their own applications.

Reports

54

Serious

47

87% of reports

Hospitalization

31

Death reported

6

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • neutropenia9
  • urinary tract infection6
  • neutrophil count decreased5
  • upper respiratory tract infection4
  • abdominal pain3
  • drug hypersensitivity3
  • headache3
  • infusion related reaction3
  • malaise3
  • off label use3
  • platelet count decreased3
  • pneumonia3
  • anaemia2
  • anaphylactic reaction2
  • cellulitis2

Reports by year received

View as table
YearReports
20212
20224
202311
202417
202511
20269

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,105 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
neutrophil count decreasedSignal547.820.7185
upper respiratory tract infectionSignal433.713.197
neutropeniaSignal925.814.2192
infusion related reactionSignal317.65.932
cellulitis215.54.015
anaphylactic reaction214.13.613
urinary tract infectionSignal613.76.459
platelet count decreasedSignal311.03.718
drug hypersensitivitySignal36.02.08
abdominal painSignal35.01.76
anaemia24.11.02
pneumonia33.61.23
malaise32.70.92
headache31.90.61
off label use31.30.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.